Intelligent management system and method for pelvic floor rehabilitation of postpartum women

Abstract

The present application discloses an intelligent management system and method for pelvic floor rehabilitation of postpartum women, and relates to the field of medical information technology, obtaining monitoring data of lesions and pelvic floor muscle contraction of postpartum patients under multiple production operations, and obtaining monitoring data of lesion changes and pelvic floor muscle recovery; monitoring postpartum patients, obtaining lesion change scores and pelvic floor muscle recovery scores before and after the use of the drug to be evaluated, and analyzing and deriving the composite score of the drug to be evaluated in postpartum patients; combining the total duration of the pelvic floor muscle contraction monitoring data of postpartum patients in the pelvic floor muscle contraction situation, calculating the evaluation of other personnel after the postpartum patients use the drug to be evaluated, as an effectiveness evaluation verification. The present invention can realize a more scientific and detailed evaluation of the use of the drug to be evaluated by postpartum patients, promote the development of effectiveness evaluation technology of postpartum patients in lesions and actual pelvic floor muscle contraction situations, and improve the product quality of the drug to be evaluated, and help the effectiveness of clinical drug testing.

Description

Technical Field

[0001] The present application relates to the field of medical information technology, and in particular to an intelligent management system and method for pelvic floor rehabilitation of postpartum women. Background Art

[0002] Postpartum recovery refers to the need for recovery and maintenance after childbirth due to physical weakness. This recovery and maintenance is called postpartum recovery. Relying on professional medical care, postpartum recovery mainly includes nutritional health product recovery and psychological counseling recovery. Women must pay attention to nutritional balance and psychological adjustment during the recovery period.

[0003] With the development of electronic communication technology, the information construction of hospitals has been continuously improved. At present, the generation and recording of various clinical biochemical indicators of patients during the diagnosis and treatment process are relatively complete. Especially in major comprehensive medical institutions, massive medical data have been generated.

[0004] However, in the prior art, it is difficult to effectively use the patient's diagnosis and treatment information to conduct rehabilitation evaluation during the pelvic floor rehabilitation process for postpartum women, which is not conducive to the pelvic floor rehabilitation of postpartum women. Summary of the invention

[0005] According to a first aspect of the present invention, the present invention claims protection for an intelligent management method for pelvic floor rehabilitation of postpartum women, which is used for postpartum patients taking a drug to be evaluated, comprising:

[0006] Obtaining the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient during multiple delivery operations, and obtaining the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing sensors;

[0007] According to the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, the postpartum patient is scored for lesion change and pelvic floor muscle recovery, and the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated are obtained;

[0008] Based on the distribution of the composite scores of the lesion changes and pelvic floor muscle recovery, the composite score of the drug to be evaluated in the postpartum patients is analyzed;

[0009] Based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of postpartum patients, the evaluation values ​​of other personnel after the postpartum patients use the drug to be evaluated are calculated to verify the effectiveness.

[0010] Furthermore, the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple delivery operations are obtained, and the lesion change monitoring data and pelvic floor muscle recovery monitoring data are obtained by wearing sensors, specifically including:

[0011] Stimulation electrodes are designated based on the delivery surgery data of the pelvic floor muscle contraction of the postpartum patient, and stimulation electrodes are designated according to the type and quantity of drugs, and multiple stimulation electrode designation groups are set to obtain multiple continuous current stimulation electrodes;

[0012] Stimulation electrodes were assigned for the lesion monitoring data and pelvic floor muscle contraction monitoring data of postpartum patients under multiple medications;

[0013] The proportion of monitoring data of stimulation electrodes and a designated group of each stimulation electrode for multiple types of postpartum patients under multiple drug states is obtained by calculation;

[0014] A hierarchical stimulation electrode designation method is used to wear the sensor, and a stimulation electrode designation group for the lesion monitoring data and a stimulation electrode designation group for the pelvic floor muscle contraction monitoring data of the postpartum patient under the compound drug are obtained according to the weights of the lesion monitoring data and the pelvic floor muscle contraction monitoring data, as the lesion change monitoring data and the pelvic floor muscle recovery monitoring data;

[0015] The designation of stimulation electrodes for the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple drugs specifically includes:

[0016] Set the intervals of multiple lesion monitoring data and pelvic floor muscle contraction monitoring data, and preset the minimum number of postpartum patients. If the total number of stimulation electrodes after designation is less than the minimum number of postpartum patients, the stimulation electrode designation is invalid.

[0017] Further, based on the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, the postpartum patient is scored for lesion change and pelvic floor muscle recovery, and the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated are obtained, specifically including:

[0018] Based on the lesion change monitoring data, the postpartum patient is scored for lesion change, and the lesion change score of the postpartum patient before and after using the drug to be evaluated is obtained;

[0019] Performing pelvic floor muscle recovery on the postpartum patient according to the pelvic floor muscle recovery monitoring data, and obtaining the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated;

[0020] According to the pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of the postpartum patient is performed to obtain the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated, specifically including:

[0021] Monitoring the composite health recovery rate of the postpartum patient under multiple drug conditions to obtain the health recovery rate of the postpartum patient without using the drug to be evaluated under the multiple drug conditions;

[0022] Using the drug to be evaluated in postpartum patients, and obtaining the health recovery rate of the postpartum patients using the drug to be evaluated under the multiple drug conditions;

[0023] The pelvic floor muscle recovery score of the postpartum patient is calculated based on the health recovery rate of the postpartum patient without using the drug to be evaluated and the health recovery rate of the postpartum patient using the drug to be evaluated.

[0024] Furthermore, when scoring the lesion changes of the postpartum patient, it specifically includes:

[0025] The control monitoring time of each lesion change monitoring data is not less than the preset period, and the average health recovery rate of each control monitoring data is recorded. After completing the monitoring of all lesion change monitoring data, the weighted health recovery rate of the postpartum patient's lesion recovery is calculated according to the weighted coefficient of each monitoring data;

[0026] Among them, according to the monitoring data of lesion changes, multiple monitoring of size change rate and activity change rate are carried out. After the lesion is stably monitored for a preset period of time, each monitoring data is compared with the monitoring time for no less than the preset period;

[0027] When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same lesion change monitoring data should not be greater than the first temperature threshold;

[0028] When performing pelvic floor muscle recovery on the postpartum patient, it specifically includes:

[0029] Based on the constructed pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients under multiple drugs and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated were carried out respectively;

[0030] Under each drug, control monitoring data monitoring is carried out according to the rate of change of deviation of pelvic floor muscle contraction of the pelvic floor muscle recovery monitoring data. The monitoring time of each control monitoring data is not less than the preset period. When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data should not be greater than the first temperature threshold. The deviation of the distance between the travel place and the historical travel place in the medication monitoring shall not exceed the first distance threshold. The deviation of the distance between the monitored travel place and the medical institution needs to meet the preset conditions.

[0031] Furthermore, based on the distribution of the composite scores of the lesion changes and the pelvic floor muscle recovery, the composite scores of the drug to be evaluated in the postpartum patients are analyzed, specifically including:

[0032] Respectively obtaining the number of adopted monitoring data of the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, and obtaining the composite score distribution of the lesion change and the pelvic floor muscle recovery according to the number of adopted monitoring data;

[0033] Determining the composite score of the drug to be evaluated in the postpartum patient according to the composite score distribution analysis;

[0034] The evaluation values ​​of other personnel after the postpartum patients use the drug to be evaluated are calculated based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients in the pelvic floor muscle contraction, and the effectiveness verification is specifically performed including:

[0035] Based on the composite score of the drug to be evaluated, the score of the time when the postpartum patient does not use the drug to be evaluated is calculated. The time score is subtracted from the score of the time when the drug to be evaluated is used to obtain the recovery rate of the postpartum patient in using the drug to be evaluated. The recovery rate is multiplied by the change rate of the postpartum patient similarity to obtain the evaluation value of other people who use the drug to be evaluated for the postpartum patient.

[0036] According to the second aspect of the present invention, the present invention claims protection for an intelligent management system for pelvic floor rehabilitation of postpartum women, comprising:

[0037] A monitoring module, which obtains the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient during multiple delivery operations, and obtains the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing sensors;

[0038] A scoring module, which performs lesion change scoring and pelvic floor muscle recovery on the postpartum patient based on the lesion change monitoring data and pelvic floor muscle recovery monitoring data, and obtains the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated;

[0039] A composite score module, which analyzes and obtains the composite score of the drug to be evaluated in the postpartum patient based on the composite score distribution of the lesion changes and pelvic floor muscle recovery;

[0040] The verification module calculates the evaluation values ​​of other people after the postpartum patients use the drug to be evaluated, based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients, to verify the effectiveness.

[0041] Furthermore, the monitoring module is specifically used for:

[0042] Stimulation electrodes are designated based on the delivery surgery data of the pelvic floor muscle contraction of the postpartum patient, and stimulation electrodes are designated according to the type and quantity of drugs, and multiple stimulation electrode designation groups are set to obtain multiple continuous current stimulation electrodes;

[0043] Stimulation electrodes were assigned for the lesion monitoring data and pelvic floor muscle contraction monitoring data of postpartum patients under multiple medications;

[0044] The proportion of monitoring data of stimulation electrodes and a designated group of each stimulation electrode for multiple types of postpartum patients under multiple drug states is obtained by calculation;

[0045] A hierarchical stimulation electrode designation method is used to wear the sensor, and a stimulation electrode designation group for the lesion monitoring data and a stimulation electrode designation group for the pelvic floor muscle contraction monitoring data of the postpartum patient under the compound drug are obtained according to the weights of the lesion monitoring data and the pelvic floor muscle contraction monitoring data, as the lesion change monitoring data and the pelvic floor muscle recovery monitoring data;

[0046] The designation of stimulation electrodes for the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple drugs specifically includes:

[0047] Set the intervals of multiple lesion monitoring data and pelvic floor muscle contraction monitoring data, and preset the minimum number of postpartum patients. If the total number of stimulation electrodes after designation is less than the minimum number of postpartum patients, the stimulation electrode designation is invalid.

[0048] Furthermore, the scoring module is specifically used for:

[0049] Based on the lesion change monitoring data, the postpartum patient is scored for lesion change, and the lesion change score of the postpartum patient before and after using the drug to be evaluated is obtained;

[0050] Performing pelvic floor muscle recovery on the postpartum patient according to the pelvic floor muscle recovery monitoring data, and obtaining the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated;

[0051] According to the pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of the postpartum patient is performed to obtain the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated, specifically including:

[0052] Monitoring the composite health recovery rate of the postpartum patient under multiple drug conditions to obtain the health recovery rate of the postpartum patient without using the drug to be evaluated under the multiple drug conditions;

[0053] Using the drug to be evaluated in postpartum patients, and obtaining the health recovery rate of the postpartum patients using the drug to be evaluated under the multiple drug conditions;

[0054] The pelvic floor muscle recovery score of the postpartum patient is calculated based on the health recovery rate of the postpartum patient without using the drug to be evaluated and the health recovery rate of the postpartum patient using the drug to be evaluated.

[0055] Furthermore, when scoring the lesion changes of the postpartum patient, it specifically includes:

[0056] The control monitoring time of each lesion change monitoring data is not less than the preset period, and the average health recovery rate of each control monitoring data is recorded. After completing the monitoring of all lesion change monitoring data, the weighted health recovery rate of the postpartum patient's lesion recovery is calculated according to the weighted coefficient of each monitoring data;

[0057] Among them, according to the monitoring data of lesion changes, multiple monitoring of size change rate and activity change rate are carried out. After the lesion is stably monitored for a preset period of time, each monitoring data is compared with the monitoring time for no less than the preset period;

[0058] When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same lesion change monitoring data should not be greater than the first temperature threshold;

[0059] When performing pelvic floor muscle recovery on the postpartum patient, it specifically includes:

[0060] Based on the constructed pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients under multiple drugs and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated were carried out respectively;

[0061] Under each drug, control monitoring data monitoring is carried out according to the rate of change of deviation of pelvic floor muscle contraction of the pelvic floor muscle recovery monitoring data. The monitoring time of each control monitoring data is not less than the preset period. When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data should not be greater than the first temperature threshold. The deviation of the distance between the travel place and the historical travel place in the medication monitoring shall not exceed the first distance threshold. The deviation of the distance between the monitored travel place and the medical institution needs to meet the preset conditions.

[0062] Furthermore, the composite scoring module is specifically used for:

[0063] Respectively obtaining the number of adopted monitoring data of the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, and obtaining the composite score distribution of the lesion change and the pelvic floor muscle recovery according to the number of adopted monitoring data;

[0064] Determining the composite score of the drug to be evaluated in the postpartum patient according to the composite score distribution analysis;

[0065] The evaluation values ​​of other personnel after the postpartum patients use the drug to be evaluated are calculated based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients in the pelvic floor muscle contraction, and the effectiveness verification is specifically performed including:

[0066] Based on the composite score of the drug to be evaluated, the score of the time when the postpartum patient does not use the drug to be evaluated is calculated. The time score is subtracted from the score of the time when the drug to be evaluated is used to obtain the recovery rate of the postpartum patient in using the drug to be evaluated. The recovery rate is multiplied by the change rate of the postpartum patient similarity to obtain the evaluation value of other people who use the drug to be evaluated for the postpartum patient.

[0067] The present invention adopts an intelligent management system and method for pelvic floor rehabilitation of postpartum women, obtains monitoring data of lesions and pelvic floor muscle contraction of postpartum patients under multiple production operations, and obtains monitoring data of lesion changes and pelvic floor muscle recovery by wearing sensors; monitors postpartum patients, obtains lesion change scores and pelvic floor muscle recovery scores before and after using the drug to be evaluated, and analyzes and obtains the composite score of the drug to be evaluated in postpartum patients; combined with the total duration of pelvic floor muscle contraction monitoring data of postpartum patients in the pelvic floor muscle contraction situation, calculates the evaluation value of other personnel after the postpartum patient uses the drug to be evaluated as effectiveness evaluation verification. The present invention can realize a more scientific and detailed evaluation of the use of the drug to be evaluated by postpartum patients, promote the development of effectiveness evaluation technology of postpartum patients in lesions and actual pelvic floor muscle contraction and improve the product quality of the drug to be evaluated, and contribute to the effectiveness of clinical drug testing. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] Figure 1 This is a work flow chart of an intelligent management method for pelvic floor rehabilitation of postpartum women involved in the present invention;

[0069] Figure 2 A second working flow chart of an intelligent management method for pelvic floor rehabilitation of postpartum women involved in the present invention;

[0070] Figure 3 A third working flow chart of an intelligent management method for pelvic floor rehabilitation of postpartum women involved in the present invention;

[0071] Figure 4 A fourth working flow chart of an intelligent management method for pelvic floor rehabilitation of postpartum women involved in the present invention;

[0072] Figure 5 This is a system structure diagram of an intelligent management system for pelvic floor rehabilitation of postpartum women involved in the present invention. DETAILED DESCRIPTION

[0073] According to the first embodiment of the present invention, referring to the attached Figure 1 The present invention claims protection for an intelligent management method for pelvic floor rehabilitation of postpartum women, which is used for postpartum patients taking drugs to be evaluated, comprising:

[0074] Obtaining the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient during multiple delivery operations, and obtaining the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing sensors;

[0075] According to the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, the postpartum patient is scored for lesion change and pelvic floor muscle recovery, and the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated are obtained;

[0076] Based on the distribution of the composite scores of the lesion changes and pelvic floor muscle recovery, the composite score of the drug to be evaluated in the postpartum patients is analyzed;

[0077] Based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients, the evaluation of other personnel after the postpartum patients used the drug to be evaluated is calculated to verify the effectiveness.

[0078] For further information, see Attachment Figure 2 , obtaining the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple delivery operations, and obtaining the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing sensors, specifically including:

[0079] Stimulation electrodes are designated based on the delivery surgery data of the pelvic floor muscle contraction of the postpartum patient, and stimulation electrodes are designated according to the type and quantity of drugs, and multiple stimulation electrode designation groups are set to obtain multiple continuous current stimulation electrodes;

[0080] Stimulation electrodes were assigned for the lesion monitoring data and pelvic floor muscle contraction monitoring data of postpartum patients under multiple medications;

[0081] The proportion of monitoring data of stimulation electrodes and a designated group of each stimulation electrode for multiple types of postpartum patients under multiple drug states is obtained by calculation;

[0082] A hierarchical stimulation electrode designation method is used to wear the sensor, and a stimulation electrode designation group for the lesion monitoring data and a stimulation electrode designation group for the pelvic floor muscle contraction monitoring data of the postpartum patient under the compound drug are obtained according to the weights of the lesion monitoring data and the pelvic floor muscle contraction monitoring data, as the lesion change monitoring data and the pelvic floor muscle recovery monitoring data;

[0083] The designation of stimulation electrodes for the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple drugs specifically includes:

[0084] Set the intervals of multiple lesion monitoring data and pelvic floor muscle contraction monitoring data, and preset the minimum number of postpartum patients. If the total number of stimulation electrodes after designation is less than the minimum number of postpartum patients, the stimulation electrode designation is invalid.

[0085] Among them, this embodiment is aimed at postpartum patients who are hospitalized, outpatients, and purchase medicines in pharmacies, and obtains pelvic floor muscle contraction monitoring data and lesion monitoring data of typical personnel from hospitalized, outpatient, and pharmacy purchasers. Through the pelvic floor muscle contraction monitoring system or video monitoring instrument, etc., combined with manual recording, the monitoring data parameters of postpartum patients are obtained. The data to be obtained at least include the amount of medication used by postpartum patients, the rate of change of lesion size (hereinafter referred to as "size"), the rate of change of activity (hereinafter referred to as "activity"), the number of drug types, and other medication log information.

[0086] Among them, in this embodiment, obtaining the lesion monitoring data of the postpartum patient under the compound drug, the stimulation electrode designation group specifically includes:

[0087] Based on the acquired pelvic floor muscle contraction data of postpartum women, a stimulation electrode designation method is used. For the pelvic floor muscle contraction monitoring data of postpartum patients, there may be multiple pelvic floor muscle contraction patterns and monitoring data. The density stimulation electrode designation method can find multiple density stimulation electrode designation clusters and has a certain robustness to noise data.

[0088] The delivery surgery specifies the stimulation electrodes according to the type and quantity of drugs, sets up multiple stimulation electrode designation groups, adopts the stimulation electrode designation method to obtain multiple continuous current stimulation electrodes, and counts the proportion of postpartum patients with multiple stimulation electrodes.

[0089] Taking the pelvic floor muscle contraction data of a certain type of postpartum patients as an example, the stimulation electrode designation of postpartum patients' drugs is explained. Stimulation electrodes are designated based on the number of types of drugs for postpartum patients. The stimulation electrode designation method is adopted to set multiple stimulation electrode designation groups, obtain multiple continuous current stimulation electrodes, and count the proportion of monitoring data of multiple stimulation electrodes.

[0090] Stimulation electrodes were assigned for the lesion monitoring data of postpartum patients under multiple drugs (size change rate, activity change rate, size change rate is the ratio of the actual size change rate to the maximum size change rate of the lesion; activity change rate is the ratio of the actual activity to the maximum activity).

[0091] This embodiment innovatively proposes to wear sensors for the monitoring locations of postpartum patients' lesion monitoring data under multiple drugs. Since the monitoring locations of the worn sensors are relatively small, a stimulation electrode designation tree structure is constructed by calculating the similarity or distance between the drugs. The drugs are gradually merged into multiple numbers of stimulation electrode designations through the tree structure. This makes stimulation electrode designation advantageous when the number of postpartum patients is small, because the number of stimulation electrode designations does not need to be determined in advance, and the stimulation electrode designations can be automatically formed based on the intrinsic structure of the data. The hierarchical stimulation electrode designation method can effectively handle the stimulation electrode designation problem of fewer drugs, and can provide multiple levels of stimulation electrode designation results, so that analysts can choose the appropriate number of stimulation electrode designations as needed.

[0092] Obtain the designated stimulation electrode group for the lesion monitoring data of postpartum patients under compound medication by wearing sensors. The designated stimulation electrode groups of external medications, solid internal medications, and liquid internal medications are worn with sensors using a hierarchical stimulation electrode designation method. In the worn sensor, if there is only one monitoring data in the designated stimulation electrode group, the designated stimulation electrode group is invalid. Pay special attention to the calculation of the weight of each designated stimulation electrode group by calculating which medication group the monitoring position point in the designated stimulation electrode group is from, for example, from the external medication group. When calculating the weight of the monitoring data, it is necessary to multiply the weight of the monitoring data in the external medication group by the weight of the external medication group.

[0093] Through the above method of specifying stimulation electrodes and wearing sensors, monitoring data and weight coefficients of lesions of a certain type of postpartum patients are constructed.

[0094] The same method was used to establish monitoring data and weight coefficients for other types of postpartum patient lesions.

[0095] The designated stimulation electrode for internal medication corresponding to the first interface hub for designating and calling the designated stimulation electrode for external medication is configured. The designated stimulation electrode for internal medication is obtained by service encapsulation based on the atomic capability configured in the first interface hub for designating and calling the designated stimulation electrode for external medication. The atomic capability is the minimum control unit obtained by decoupling the perception action of the environmental perception device within the monitoring domain of the dynamic medication monitor.

[0096] Receive the instructions uploaded by the first interface hub for designating and calling the external medication designated stimulation electrode through the upload interface provided by the corresponding internal medication designated stimulation electrode, and send the instructions corresponding to the internal medication designated stimulation electrode to the environmental sensing device within the monitoring domain of the dynamic medication monitor.

[0097] For further information, see Attachment Figure 3, based on the lesion change monitoring data and pelvic floor muscle recovery monitoring data, the postpartum patient is scored for lesion change and pelvic floor muscle recovery, and the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated are obtained, specifically including:

[0098] Based on the lesion change monitoring data, the postpartum patient is scored for lesion change, and the lesion change score of the postpartum patient before and after using the drug to be evaluated is obtained;

[0099] Performing pelvic floor muscle recovery on the postpartum patient according to the pelvic floor muscle recovery monitoring data, and obtaining the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated;

[0100] For further information, see Attachment Figure 4 , based on the pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of the postpartum patient is performed to obtain the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated, specifically including:

[0101] Monitoring the composite health recovery rate of the postpartum patient under multiple drug conditions to obtain the health recovery rate of the postpartum patient without using the drug to be evaluated under the multiple drug conditions;

[0102] Using the drug to be evaluated in postpartum patients, and obtaining the health recovery rate of the postpartum patients using the drug to be evaluated under the multiple drug conditions;

[0103] The pelvic floor muscle recovery score of the postpartum patient is calculated based on the health recovery rate of the postpartum patient without using the drug to be evaluated and the health recovery rate of the postpartum patient using the drug to be evaluated.

[0104] Furthermore, when scoring the lesion changes of the postpartum patient, it specifically includes:

[0105] The control monitoring time of each lesion change monitoring data is not less than the preset period, and the average health recovery rate of each control monitoring data is recorded. After completing the monitoring of all lesion change monitoring data, the weighted health recovery rate of the postpartum patient's lesion recovery is calculated according to the weighted coefficient of each monitoring data;

[0106] Among them, according to the monitoring data of lesion changes, multiple monitoring of size change rate and activity change rate are carried out. After the lesion is stably monitored for a preset period of time, each monitoring data is compared with the monitoring time for no less than the preset period;

[0107] When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same lesion change monitoring data should not be greater than the first temperature threshold;

[0108] When performing pelvic floor muscle recovery on the postpartum patient, it specifically includes:

[0109] Based on the constructed pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients under multiple drugs and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated were carried out respectively;

[0110] Under each drug, control monitoring data monitoring is carried out according to the rate of change of deviation of pelvic floor muscle contraction of the pelvic floor muscle recovery monitoring data. The monitoring time of each control monitoring data is not less than the preset period. When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data should not be greater than the first temperature threshold. The deviation of the distance between the travel place and the historical travel place in the medication monitoring shall not exceed the first distance threshold. The deviation of the distance between the monitored travel place and the medical institution needs to meet the preset conditions.

[0111] Furthermore, based on the distribution of the composite scores of the lesion changes and the pelvic floor muscle recovery, the composite scores of the drug to be evaluated in the postpartum patients are analyzed, specifically including:

[0112] Respectively obtaining the number of adopted monitoring data of the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, and obtaining the composite score distribution of the lesion change and the pelvic floor muscle recovery according to the number of adopted monitoring data;

[0113] Determining the composite score of the drug to be evaluated in the postpartum patient according to the composite score distribution analysis;

[0114] The evaluation values ​​of other personnel after the postpartum patients use the drug to be evaluated are calculated based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients in the pelvic floor muscle contraction, and the effectiveness verification is specifically performed including:

[0115] Based on the composite score of the drug to be evaluated, the score of the time when the postpartum patient does not use the drug to be evaluated is calculated. The time score is subtracted from the score of the time when the drug to be evaluated is used to obtain the recovery rate of the postpartum patient in using the drug to be evaluated. The recovery rate is multiplied by the change rate of the postpartum patient similarity to obtain the evaluation value of other people who use the drug to be evaluated for the postpartum patient.

[0116] Other personnel evaluate postpartum patients who have taken the drug to be evaluated, give evaluation values, and evaluate the patient's recovery effect. The evaluation values ​​of other personnel can be used to support and verify the effect of the drug to be evaluated.

[0117] According to the second embodiment of the present invention, referring to the attached Figure 5 The present invention claims protection for an intelligent management system for pelvic floor rehabilitation of postpartum women, comprising:

[0118] A monitoring module, which obtains the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient during multiple delivery operations, and obtains the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing sensors;

[0119] A scoring module, which performs lesion change scoring and pelvic floor muscle recovery on the postpartum patient based on the lesion change monitoring data and pelvic floor muscle recovery monitoring data, and obtains the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated;

[0120] A composite score module, which analyzes and obtains the composite score of the drug to be evaluated in the postpartum patient based on the composite score distribution of the lesion changes and pelvic floor muscle recovery;

[0121] The verification module calculates the evaluation values ​​of other people after the postpartum patients use the drug to be evaluated, based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients, to verify the effectiveness.

[0122] Furthermore, the monitoring module is specifically used for:

[0123] Stimulation electrodes are designated based on the delivery surgery data of the pelvic floor muscle contraction of the postpartum patient, and stimulation electrodes are designated according to the type and quantity of drugs, and multiple stimulation electrode designation groups are set to obtain multiple continuous current stimulation electrodes;

[0124] Stimulation electrodes were assigned for the lesion monitoring data and pelvic floor muscle contraction monitoring data of postpartum patients under multiple medications;

[0125] The proportion of monitoring data of stimulation electrodes and a designated group of each stimulation electrode for multiple types of postpartum patients under multiple drug states is obtained by calculation;

[0126] A hierarchical stimulation electrode designation method is used to wear the sensor, and a stimulation electrode designation group for the lesion monitoring data and a stimulation electrode designation group for the pelvic floor muscle contraction monitoring data of the postpartum patient under the compound drug are obtained according to the weights of the lesion monitoring data and the pelvic floor muscle contraction monitoring data, as the lesion change monitoring data and the pelvic floor muscle recovery monitoring data;

[0127] The designation of stimulation electrodes for the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple drugs specifically includes:

[0128] Set the intervals of multiple lesion monitoring data and pelvic floor muscle contraction monitoring data, and preset the minimum number of postpartum patients. If the total number of stimulation electrodes after designation is less than the minimum number of postpartum patients, the stimulation electrode designation is invalid.

[0129] Furthermore, the scoring module is specifically used for:

[0130] Based on the lesion change monitoring data, the postpartum patient is scored for lesion change, and the lesion change score of the postpartum patient before and after using the drug to be evaluated is obtained;

[0131] Performing pelvic floor muscle recovery on the postpartum patient according to the pelvic floor muscle recovery monitoring data, and obtaining the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated;

[0132] According to the pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of the postpartum patient is performed to obtain the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated, specifically including:

[0133] Monitoring the composite health recovery rate of the postpartum patient under multiple drug conditions to obtain the health recovery rate of the postpartum patient without using the drug to be evaluated under the multiple drug conditions;

[0134] Using the drug to be evaluated in postpartum patients, and obtaining the health recovery rate of the postpartum patients using the drug to be evaluated under the multiple drug conditions;

[0135] The pelvic floor muscle recovery score of the postpartum patient is calculated based on the health recovery rate of the postpartum patient without using the drug to be evaluated and the health recovery rate of the postpartum patient using the drug to be evaluated.

[0136] Furthermore, when scoring the lesion changes of the postpartum patient, it specifically includes:

[0137] The control monitoring time of each lesion change monitoring data is not less than the preset period, and the average health recovery rate of each control monitoring data is recorded. After completing the monitoring of all lesion change monitoring data, the weighted health recovery rate of the postpartum patient's lesion recovery is calculated according to the weighted coefficient of each monitoring data;

[0138] Among them, according to the monitoring data of lesion changes, multiple monitoring of size change rate and activity change rate are carried out. After the lesion is stably monitored for a preset period of time, each monitoring data is compared with the monitoring time for no less than the preset period;

[0139] When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same lesion change monitoring data should not be greater than the first temperature threshold;

[0140] When performing pelvic floor muscle recovery on the postpartum patient, it specifically includes:

[0141] Based on the constructed pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients under multiple drugs and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated were carried out respectively;

[0142] Under each drug, control monitoring data monitoring is carried out according to the rate of change of deviation of pelvic floor muscle contraction of the pelvic floor muscle recovery monitoring data. The monitoring time of each control monitoring data is not less than the preset period. When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data should not be greater than the first temperature threshold. The deviation of the distance between the travel place and the historical travel place in the medication monitoring shall not exceed the first distance threshold. The deviation of the distance between the monitored travel place and the medical institution needs to meet the preset conditions.

[0143] Among them, in this embodiment, the stimulation electrode designated group of monitoring data of pelvic floor muscle contraction of postpartum patients under compound medication specifically includes:

[0144] The score of postpartum patients using the drug to be evaluated is a key evaluation indicator of the effectiveness of the drug in the actual pelvic floor muscle contraction of postpartum patients. Since postpartum patients are susceptible to many factors such as their own monitoring data in the actual pelvic floor muscle contraction, the duration of postpartum patients cannot be characterized and measured by a single parameter. When the pelvic floor muscles of postpartum patients are actually contracted, the amount of medication, lesion monitoring data (size change rate, activity change rate), and the number of drug types collected by the patient sensor can usually be used. This embodiment calculates the correlation coefficient between the pelvic floor muscle contraction parameters and the duration of postpartum patients based on the pelvic floor muscle contraction parameters and duration data of postpartum patients. Among them, it includes evaluating the linear correlation between the two variables and evaluating the nonlinear correlation between the two variables. According to the correlation coefficient between the pelvic floor muscle contraction parameters of postpartum patients and the duration of postpartum patients, a parameter with a correlation coefficient between [-2,2] is selected as a parameter for constructing monitoring data.

[0145] The number of drug types, the ratio of drug usage, the size of lesions, and the activity of postpartum patients have a high linear correlation with the duration of medication for postpartum patients, while the nonlinear correlation between other parameters and the duration is low. Since the activity parameters of postpartum patients are relatively difficult to obtain in the actual monitoring experiment of postpartum patients, this plan uses the number of drug types, the ratio of drug usage, and the size of lesions as the main parameters for evaluating the duration of pelvic floor muscle contraction in postpartum patients.

[0146] Among them, in this embodiment, taking the monitoring of postpartum patients who have not used the drugs to be evaluated as an example, the calculation method of the composite health recovery rate of the patient's lesions according to the monitoring data is shown in Formula 1.

[0147] ;

[0148] It indicates the composite health recovery rate of postpartum patients who did not use the drugs to be evaluated;

[0149] Indicates the duration score of the lesion monitoring location point;

[0150] Indicates the lesion monitoring location point activity level;

[0151] Indicates each monitoring data The weight coefficient of .

[0152] The same calculation method is used to calculate the composite health recovery rate of postpartum patients using the drugs to be evaluated .

[0153] After obtaining the composite health recovery rate of lesion changes of postpartum patients before and after using the drug to be evaluated, the lesion change score of the drug to be evaluated for the patient is calculated using Formula 2.

[0154] ;

[0155] Where:

[0156] Indicates the lesion change score.

[0157] Furthermore, based on the pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients is performed to obtain the pelvic floor muscle recovery scores of postpartum patients before and after using the drug to be evaluated, including:

[0158] The composite health recovery rate of postpartum patients under multiple drug conditions is monitored to obtain the health recovery rate of postpartum patients without using the drugs to be evaluated under multiple drug conditions;

[0159] Using the drug to be evaluated in postpartum patients, and obtaining the health recovery rate of the postpartum patients using the drug to be evaluated under the multiple drug conditions;

[0160] The pelvic floor muscle recovery score of postpartum patients was calculated based on the health recovery rate of postpartum patients who did not use the drugs to be evaluated and those who used the drugs to be evaluated.

[0161] Among them, in this embodiment, postpartum patients are monitored under topical medications, solid oral medications, and liquid oral medications (0%, 50%, and 90% medications), and the deviation rate of the pelvic floor muscle contraction situation of the monitoring data is monitored. Postpartum patients are monitored before and after using the drugs to be evaluated. In the same monitoring data before and after monitoring, the monitoring data of the lesions, historical travel places, and medical institutions all maintain a similar range to the above requirements.

[0162] According to the monitoring location of the postpartum patient's lesion i The duration score of the pelvic floor muscle contraction of postpartum patients is at the monitoring position pointi The distance traveled and the postpartum patients in each monitoring data j The weight coefficient of the composite health recovery rate monitoring under the same drug is obtained:

[0163] And use the same method to calculate the health recovery rate under other drugs;

[0164] According to the weight coefficient of postpartum patients under drug k and under A k Under drug conditions, the health recovery rate of postpartum patients who did not use the drugs to be evaluated was calculated, and the composite health recovery rate of postpartum patients who did not use the drugs to be evaluated under multiple drugs was calculated:

[0165] Based on A k Under drug conditions, the health recovery rate of postpartum patients using the drugs to be evaluated and the weight coefficient of postpartum patients under k drugs are used to calculate the composite health recovery rate of postpartum patients using the drugs to be evaluated under multiple drugs:

[0166] After obtaining the composite health recovery rate actually measured by the postpartum patients before and after using the drug to be evaluated, the pelvic floor muscle recovery score of the drug to be evaluated for the patient is calculated.

[0167] Among them, according to the monitoring data of lesion changes, multiple monitoring of size change rate and activity change rate are carried out. After the lesion is stably monitored for a preset period of time, each monitoring data is compared with the monitoring time for no less than the preset period;

[0168] When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same lesion change monitoring data should not be greater than the first temperature threshold;

[0169] Among them, in this embodiment, based on the constructed lesion monitoring data, the monitoring of the lesions of postpartum patients and the monitoring of the use of a certain proportion of the drugs to be evaluated by postpartum patients are carried out respectively, and the control monitoring time of each monitoring data is not less than 30 minutes, and the average health recovery rate of each control monitoring data is recorded. After all the monitoring data are completed, the weighted health recovery rate of the lesions of postpartum patients is calculated according to the weighted coefficient of each monitoring data. After the changes in the lesions of postpartum patients before and after using the drugs to be evaluated are all completed, the score of the drug to be evaluated in the changes in the lesions of postpartum patients is calculated based on the weighted health recovery rate before and after using the drugs to be evaluated.

[0170] When performing pelvic floor muscle rehabilitation for postpartum patients, it specifically includes:

[0171] Based on the constructed pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients under multiple drugs and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated were carried out respectively;

[0172] Under each drug, control monitoring data monitoring is carried out based on the rate of change of deviation of pelvic floor muscle contraction in pelvic floor muscle recovery monitoring data. The monitoring time of each control monitoring data shall not be less than the preset period. When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data shall not be greater than the first temperature threshold. The deviation of the distance between the travel place and the historical travel place in medication monitoring shall not exceed the first distance threshold. The deviation of the distance between the monitored travel place and the medical institution shall meet the preset conditions.

[0173] Among them, in this embodiment, based on the constructed monitoring data of pelvic floor muscle contraction of postpartum patients, the pelvic floor muscle recovery of postpartum patients under multiple drugs (external drugs, solid oral drugs, liquid oral drugs) and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated are carried out respectively, and the control monitoring data are monitored according to the rate of change of the deviation of pelvic floor muscle contraction under each drug respectively. The monitoring time of each control monitoring data is not less than 30 minutes. When monitoring before and after the healthy use of the drugs to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data should not be greater than 2°C, and the deviation of the distance between the travel place and the historical travel place in the two monitorings before and after the use of the drugs shall not exceed 2km, and the deviation of the distance between the travel place and the medical institution in the two monitorings before and after the use of the drugs shall not exceed 45º. Record the duration of postpartum patients and the distance traveled by pelvic floor muscle contraction under each control monitoring data. After completing all monitoring data monitoring, calculate the health recovery rate under each monitoring data, calculate the health recovery rate of postpartum patients under each drug based on the monitoring data weight coefficient, and calculate the composite health recovery rate of the actual pelvic floor muscle contraction of postpartum patients based on the weight coefficient of each drug. Then, use the same method to calculate the composite health recovery rate of postpartum patients after healthy use of the drugs to be evaluated; based on the composite health recovery rate of postpartum patients before and after healthy use of the drugs to be evaluated, calculate the score of pelvic floor muscle recovery of postpartum patients using the drugs to be evaluated.

[0174] Furthermore, based on the distribution of composite scores of lesion changes and pelvic floor muscle recovery, the composite scores of the drugs to be evaluated in postpartum patients were analyzed, including:

[0175] The number of adopted monitoring data of lesion change monitoring data and pelvic floor muscle recovery monitoring data is respectively obtained, and the composite score distribution of lesion change and pelvic floor muscle recovery is obtained according to the number of adopted monitoring data;

[0176] The composite score of the drug to be evaluated in postpartum patients was obtained based on the composite score distribution analysis.

[0177] Furthermore, the composite scoring module is specifically used for:

[0178] Respectively obtaining the number of adopted monitoring data of the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, and obtaining the composite score distribution of the lesion change and the pelvic floor muscle recovery according to the number of adopted monitoring data;

[0179] Determining the composite score of the drug to be evaluated in the postpartum patient according to the composite score distribution analysis;

[0180] The evaluation values ​​of other personnel after the postpartum patients use the drug to be evaluated are calculated based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients in the pelvic floor muscle contraction, and the effectiveness verification is specifically performed including:

[0181] Based on the composite score of the drug to be evaluated, the score of the time when the postpartum patient does not use the drug to be evaluated is calculated. The time score is subtracted from the score of the time when the drug to be evaluated is used to obtain the recovery rate of the postpartum patient in using the drug to be evaluated. The recovery rate is multiplied by the change rate of the postpartum patient similarity to obtain the evaluation value of other people who use the drug to be evaluated for the postpartum patient.

[0182] Among them, in this embodiment, after the postpartum patient uses the drug to be evaluated, based on the total duration of a course of treatment obtained by the postpartum patient, and according to the composite score of the drug to be evaluated, the evaluation value of the postpartum patient in a course of treatment by other personnel is calculated. Based on the composite score of the drug to be evaluated, the time score of the postpartum patient not using the drug to be evaluated is calculated, and then the health recovery rate of using the drug to be evaluated is subtracted from the obtained time score, that is, the recovery rate of the postpartum patient using the drug to be evaluated in this course of treatment is obtained, and the recovery rate is multiplied by the change rate of the similarity of the postpartum patient, and the evaluation value of the postpartum patient using the drug to be evaluated in this course of treatment can be obtained.

[0183] Those skilled in the art will appreciate that the contents disclosed in this disclosure may be subject to various modifications and improvements. For example, the various devices or components described above may be implemented by hardware, or by software, firmware, or a combination of some or all of the three.

[0184] Flowcharts are used in this disclosure to illustrate the steps of the method according to the embodiments of the present disclosure. It should be understood that the preceding or following steps are not necessarily performed precisely in order. Instead, various steps may be processed in reverse order or simultaneously. At the same time, other operations may also be used in these processes.

[0185] Those skilled in the art will appreciate that all or part of the steps in the above method can be completed by instructing related hardware through a computer program, and the program can be stored in a computer-readable storage medium, such as a read-only memory, a disk, or an optical disk. Optionally, all or part of the steps in the above embodiment can also be implemented using one or more integrated circuits. Accordingly, each module / unit in the above embodiment can be implemented in the form of hardware or in the form of a software functional module. The present disclosure is not limited to any particular form of combination of hardware and software.

[0186] Unless otherwise defined, all terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present disclosure belongs. It should also be understood that terms such as those defined in common dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an idealized or highly formal sense, unless explicitly defined as such herein.

[0187] The above is an explanation of the present disclosure and should not be considered as a limitation thereof. Although several exemplary embodiments of the present disclosure are described, it will be readily understood by those skilled in the art that many modifications may be made to the exemplary embodiments without departing from the novel teachings and advantages of the present disclosure. Therefore, all such modifications are intended to be included within the scope of the present disclosure as defined in the claims. It should be understood that the above is an explanation of the present disclosure and should not be considered to be limited to the specific embodiments disclosed, and modifications to the disclosed embodiments and other embodiments are intended to be included within the scope of the appended claims. The present disclosure is defined by the claims and their equivalents.

[0188] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.

[0189] Although the embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the claims and their equivalents.

Claims

1. An intelligent management method for pelvic floor rehabilitation of postpartum women, characterized in that: For postpartum patients taking medications to be evaluated, including: Obtaining the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient during multiple delivery operations, and obtaining the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing sensors; According to the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, the postpartum patient is scored for lesion change and pelvic floor muscle recovery, and the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated are obtained; Based on the distribution of the composite scores of the lesion changes and pelvic floor muscle recovery, the composite score of the drug to be evaluated in the postpartum patients is analyzed; Based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patient, the evaluation values ​​of other personnel after the postpartum patient uses the drug to be evaluated are calculated to verify the effectiveness; According to the lesion change monitoring data and pelvic floor muscle recovery monitoring data, the postpartum patient is scored for lesion change and pelvic floor muscle recovery, and the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated are obtained, specifically including: Based on the lesion change monitoring data, the postpartum patient is scored for lesion change, and the lesion change score of the postpartum patient before and after using the drug to be evaluated is obtained; Performing pelvic floor muscle recovery on the postpartum patient according to the pelvic floor muscle recovery monitoring data, and obtaining the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated; According to the pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of the postpartum patient is performed to obtain the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated, specifically including: Monitoring the composite health recovery rate of the postpartum patient under multiple drug conditions to obtain the health recovery rate of the postpartum patient without using the drug to be evaluated under the multiple drug conditions; Using the drug to be evaluated in postpartum patients, and obtaining the health recovery rate of the postpartum patients using the drug to be evaluated under the multiple drug conditions; Calculate the pelvic floor muscle recovery score of the postpartum patient based on the health recovery rate of the postpartum patient without using the drug to be evaluated and the health recovery rate of the postpartum patient using the drug to be evaluated; Based on the distribution of the composite scores of the lesion changes and pelvic floor muscle recovery, the composite scores of the drug to be evaluated in the postpartum patients are analyzed, specifically including: Respectively obtaining the number of adopted monitoring data of the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, and obtaining the composite score distribution of the lesion change and the pelvic floor muscle recovery according to the number of adopted monitoring data; Determining the composite score of the drug to be evaluated in the postpartum patient according to the composite score distribution analysis; The evaluation values ​​of other personnel after the postpartum patients use the drug to be evaluated are calculated based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients in the pelvic floor muscle contraction, and the effectiveness verification is specifically performed including: Based on the composite score of the drug to be evaluated, the time score of the postpartum patient not using the drug to be evaluated is calculated, and the recovery rate of the postpartum patient using the drug to be evaluated is obtained by subtracting the time score of using the drug to be evaluated from the obtained time score, and the recovery rate is multiplied by the similarity change rate of the postpartum patient to obtain the evaluation value of other personnel who used the drug to be evaluated for the postpartum patient; Obtaining the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple delivery operations, and obtaining the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing sensors, specifically including: Stimulation electrodes are designated based on the delivery surgery data of the pelvic floor muscle contraction of the postpartum patient, and stimulation electrodes are designated according to the type and quantity of drugs, and multiple stimulation electrode designation groups are set to obtain multiple continuous current stimulation electrodes; Stimulation electrodes were assigned to the lesion monitoring data and pelvic floor muscle contraction monitoring data of postpartum patients under multiple medications; The monitoring data proportion of stimulation electrodes and each stimulation electrode designated group of multiple types of postpartum patients under multiple drug states is obtained by calculation; A hierarchical stimulation electrode designation method is used to wear the sensor, and a stimulation electrode designation group for the lesion monitoring data and a stimulation electrode designation group for the pelvic floor muscle contraction monitoring data of the postpartum patient under the compound drug are obtained according to the weights of the lesion monitoring data and the pelvic floor muscle contraction monitoring data, as the lesion change monitoring data and the pelvic floor muscle recovery monitoring data; The designation of stimulation electrodes for the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple drugs specifically includes: Set the intervals of multiple lesion monitoring data and pelvic floor muscle contraction monitoring data, and preset the minimum number of postpartum patients. If the total number of stimulation electrodes after designation is less than the minimum number of postpartum patients, the stimulation electrode designation is invalid.

2. The intelligent management method for pelvic floor rehabilitation of postpartum women according to claim 1, characterized in that: When scoring the lesion changes of the postpartum patients, the following are specifically included: The control monitoring time of each lesion change monitoring data is not less than the preset period, and the average health recovery rate of each control monitoring data is recorded. After completing the monitoring of all lesion change monitoring data, the weighted health recovery rate of the postpartum patient's lesion recovery is calculated according to the weighted coefficient of each monitoring data; Among them, according to the monitoring data of lesion changes, multiple monitoring of size change rate and activity change rate are carried out. After the lesion is stably monitored for a preset period of time, each monitoring data is compared with the monitoring time for no less than the preset period; When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same lesion change monitoring data should not be greater than the first temperature threshold; When performing pelvic floor muscle recovery on the postpartum patient, it specifically includes: Based on the constructed pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients under multiple drugs and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated were carried out respectively; Under each drug, control monitoring data monitoring is carried out according to the rate of change of deviation of pelvic floor muscle contraction of the pelvic floor muscle recovery monitoring data. The monitoring time of each control monitoring data is not less than the preset period. When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data should not be greater than the first temperature threshold. The deviation of the distance between the travel place and the historical travel place in the medication monitoring shall not exceed the first distance threshold. The deviation of the distance between the monitored travel place and the medical institution needs to meet the preset conditions.

3. An intelligent management system for pelvic floor rehabilitation of postpartum women, characterized in that: For postpartum patients taking medications to be evaluated, including: A monitoring module, used to obtain the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple delivery operations, and to obtain the lesion change monitoring data and pelvic floor muscle recovery monitoring data by wearing a sensor method; A scoring module, for scoring the lesion change and pelvic floor muscle recovery of the postpartum patient based on the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, and obtaining the lesion change score and pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated; A composite score module, used to analyze and obtain the composite score of the drug to be evaluated in the postpartum patient based on the composite score distribution of the lesion changes and pelvic floor muscle recovery; A verification module, for calculating the evaluation values ​​of other personnel after the postpartum patient uses the drug to be evaluated based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patient in the pelvic floor muscle contraction condition, and performing effectiveness verification; The scoring module is specifically used for: Based on the lesion change monitoring data, the postpartum patient is scored for lesion change, and the lesion change score of the postpartum patient before and after using the drug to be evaluated is obtained; Performing pelvic floor muscle recovery on the postpartum patient according to the pelvic floor muscle recovery monitoring data, and obtaining the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated; According to the pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of the postpartum patient is performed to obtain the pelvic floor muscle recovery score of the postpartum patient before and after using the drug to be evaluated, specifically including: Monitoring the composite health recovery rate of the postpartum patient under multiple drug conditions to obtain the health recovery rate of the postpartum patient without using the drug to be evaluated under the multiple drug conditions; Using the drug to be evaluated in postpartum patients, and obtaining the health recovery rate of the postpartum patients using the drug to be evaluated under the multiple drug conditions; Calculate the pelvic floor muscle recovery score of the postpartum patient based on the health recovery rate of the postpartum patient without using the drug to be evaluated and the health recovery rate of the postpartum patient using the drug to be evaluated; The composite scoring module is specifically used for: Respectively obtaining the number of adopted monitoring data of the lesion change monitoring data and the pelvic floor muscle recovery monitoring data, and obtaining the composite score distribution of the lesion change and the pelvic floor muscle recovery according to the number of adopted monitoring data; Determining the composite score of the drug to be evaluated in the postpartum patient according to the composite score distribution analysis; The evaluation values ​​of other personnel after the postpartum patients use the drug to be evaluated are calculated based on the obtained composite score of the drug to be evaluated and the total duration of the pelvic floor muscle contraction monitoring data of the postpartum patients in the pelvic floor muscle contraction, and the effectiveness verification is specifically performed including: Based on the composite score of the drug to be evaluated, the time score of the postpartum patient not using the drug to be evaluated is calculated, and the recovery rate of the postpartum patient using the drug to be evaluated is obtained by subtracting the time score of using the drug to be evaluated from the obtained time score, and the recovery rate is multiplied by the similarity change rate of the postpartum patient to obtain the evaluation value of other personnel who used the drug to be evaluated for the postpartum patient; The monitoring module is specifically used for: Stimulation electrodes are designated based on the delivery surgery data of the pelvic floor muscle contraction of the postpartum patient, and stimulation electrodes are designated according to the type and quantity of drugs, and multiple stimulation electrode designation groups are set to obtain multiple continuous current stimulation electrodes; Stimulation electrodes were assigned to the lesion monitoring data and pelvic floor muscle contraction monitoring data of postpartum patients under multiple medications; The monitoring data proportion of stimulation electrodes and each stimulation electrode designated group of multiple types of postpartum patients under multiple drug states is obtained by calculation; A hierarchical stimulation electrode designation method is used to wear the sensor, and a stimulation electrode designation group for the lesion monitoring data and a stimulation electrode designation group for the pelvic floor muscle contraction monitoring data of the postpartum patient under the compound drug are obtained according to the weights of the lesion monitoring data and the pelvic floor muscle contraction monitoring data, as the lesion change monitoring data and the pelvic floor muscle recovery monitoring data; The designation of stimulation electrodes for the lesion monitoring data and pelvic floor muscle contraction monitoring data of the postpartum patient under multiple drugs specifically includes: Setting intervals for multiple lesion monitoring data and pelvic floor muscle contraction monitoring data, and presetting a minimum number of postpartum patients, if the total number of stimulation electrodes after designation is less than the minimum number of postpartum patients, the stimulation electrode designation is invalid; When scoring the lesion changes of the postpartum patients, the following are specifically included: The control monitoring time of each lesion change monitoring data is not less than the preset period, and the average health recovery rate of each control monitoring data is recorded. After completing the monitoring of all lesion change monitoring data, the weighted health recovery rate of the postpartum patient's lesion recovery is calculated according to the weighted coefficient of each monitoring data; Among them, according to the monitoring data of lesion changes, multiple monitoring of size change rate and activity change rate are carried out. After the lesion is stably monitored for a preset period of time, each monitoring data is compared with the monitoring time for no less than the preset period; When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same lesion change monitoring data should not be greater than the first temperature threshold; When performing pelvic floor muscle recovery on the postpartum patient, it specifically includes: Based on the constructed pelvic floor muscle recovery monitoring data, the pelvic floor muscle recovery of postpartum patients under multiple drugs and the pelvic floor muscle recovery of postpartum patients using a certain proportion of drugs to be evaluated were carried out respectively; Under each drug, control monitoring data monitoring is carried out according to the rate of change of deviation of pelvic floor muscle contraction of the pelvic floor muscle recovery monitoring data. The monitoring time of each control monitoring data is not less than the preset period. When monitoring before and after the healthy use of the drug to be evaluated, the difference in infrared detection temperature before and after the lesion under the same monitoring data should not be greater than the first temperature threshold. The deviation of the distance between the travel place and the historical travel place in the medication monitoring shall not exceed the first distance threshold. The deviation of the distance between the monitored travel place and the medical institution needs to meet the preset conditions.

Images